As Ontario continues the battle against COVID-19, strategies such as vaccination and following other public health safety precautions remain essential. To further support patients, OPA has been advocating to enable pharmacists to prescribe nirmatrelvir/ritonavir (Paxlovid) as access to and use of COVID-19 treatments for high-risk patients are important to prevent serious outcomes from COVID-19 infection […]
This page is only available to members. log in become a member